Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Preventing Malignant Transformation in Oral Lichen Planus
NCT06533033Active, not recruiting
- Start
- Jan 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Mucomel in oral lichen planus (OLP) (2 arms). Primary endpoints: Change in DNA methylation level of tumor suppressor gene (ZNF582) at 8 weeks, Change in oral lesions at 12 weeks and 3 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
Mucomel
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on NCT06533033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533033.